A PET/CT scan is a two-in-one imaging test that combines a PET (positron emission tomography) scanner with a CT (computed tomography) scanner in a single machine. The CT portion creates detailed anatomical images of your body’s structures, while the PET portion reveals metabolic activity, showing how actively your cells are using energy. Together, they produce a fused image that lets doctors see both where something is in your body and whether it’s behaving abnormally. The scan is most commonly used to detect, stage, and monitor cancer, though it also plays a role in evaluating heart disease, epilepsy, and Alzheimer’s disease.
How the Two Scans Work Together
CT scans use X-rays to build a precise 3D map of your anatomy. They’re excellent at showing size, shape, and location of structures, but they can’t tell you much about what those structures are doing. A lymph node might look slightly enlarged on CT, but that could mean cancer, a past infection, or simple inflammation. CT alone often can’t distinguish between them.
PET fills that gap by measuring metabolic activity. Before the scan, you receive an injection of a radioactive tracer, most commonly a modified sugar molecule called FDG. Your cells take up this tracer the same way they take up regular glucose. The key difference is that once FDG enters a cell and gets processed, it becomes trapped inside rather than being broken down further. Cells that are burning through a lot of energy, like cancer cells, accumulate far more of the tracer than normal tissue, and they light up on the PET image.
When you overlay the PET’s metabolic “hot spots” onto the CT’s anatomical map, the result is remarkably useful. A suspicious mass on CT that shows intense tracer uptake is much more likely to be malignant. Conversely, an area that looks worrisome on CT but shows normal metabolic activity may be scar tissue or a benign change. This combination reduces ambiguity in both directions: subtle PET findings that might be dismissed as normal can be flagged once they line up with a structural abnormality on CT, and unclear CT findings can be clarified by the metabolic data.
Why Cancer Cells Light Up
Cancer cells consume glucose at a much higher rate than most healthy cells. This is partly because tumors grow rapidly and partly because many cancer cells rely on an inefficient form of energy production that requires more sugar to fuel. FDG exploits this difference. Over 90% of oncologic PET imaging uses FDG, and it remains the only PET tracer approved by the FDA for routine clinical use. The uptake is substantially increased in most common cancers, including lung, colorectal, breast, head and neck, cervical, ovarian, and esophageal cancers, as well as melanoma and most types of lymphoma.
Not every cancer shows up equally well on FDG-PET. Some slower-growing tumors, like certain prostate cancers, don’t consume enough glucose to produce a strong signal. For prostate cancer specifically, newer tracers targeting a protein called PSMA on the surface of prostate cancer cells have become an important alternative. Other specialized tracers exist for neuroendocrine tumors and certain brain cancers, though FDG remains the workhorse for the vast majority of scans.
What PET/CT Is Used For
In oncology, PET/CT serves several distinct purposes. At initial diagnosis, it helps determine how far cancer has spread, a process called staging. Knowing whether cancer is confined to one area or has reached distant organs is essential for choosing the right treatment. PET/CT can also detect recurrence, sometimes picking up returning cancer through elevated tracer uptake before any structural changes are visible on a standard CT scan. This is especially valuable when blood markers suggest recurrence but conventional imaging looks normal.
During treatment, PET/CT helps gauge whether chemotherapy, immunotherapy, or radiation is working. A tumor that shows reduced metabolic activity after a few cycles of treatment is responding. One that remains highly active may prompt doctors to switch strategies early rather than continuing an ineffective regimen. The European Society for Hybrid, Molecular and Translational Imaging considers PET/CT indispensable for evaluating disease extent and treatment response, with a high level of evidence supporting its role in detecting non-responding tumors early enough to change course.
Beyond cancer, PET/CT has established roles in cardiology and neurology. In the heart, it can assess blood flow to the heart muscle and determine whether damaged tissue is still viable, helping decide if procedures to restore blood flow would be worthwhile. In the brain, it helps evaluate Alzheimer’s disease by revealing characteristic patterns of reduced metabolic activity in specific regions. It’s also used to pinpoint seizure-originating areas in epilepsy patients being considered for surgery.
What to Expect Before and During the Scan
Preparation centers on controlling your blood sugar, since the tracer is a glucose-based molecule. You’ll need to fast for about 12 hours beforehand, drinking only plain water. On the day of the scan, your blood glucose needs to be below 175 mg/dL. If it’s above that threshold, the scan may need to be rescheduled because high blood sugar competes with the tracer for uptake into cells, reducing image quality. If you have diabetes, your care team will give you specific instructions about managing your medications during the fasting period.
At the imaging center, you’ll receive the FDG injection through an IV line, then sit or lie quietly for about 60 minutes. This uptake period, typically 55 to 75 minutes, gives the tracer time to distribute through your body and accumulate in metabolically active tissues. You’ll be asked to avoid physical activity during this time because exercising muscles also consume glucose and could create misleading signals on the images.
The scan itself takes place on a table that slides through a large, donut-shaped scanner. The CT portion takes just seconds to minutes. The PET portion is slower, typically 15 to 30 minutes for a whole-body scan. You’ll need to lie still throughout. The entire visit, from arrival through injection, waiting, and scanning, usually takes two to three hours.
Radiation Exposure
A PET/CT scan involves radiation from two sources: the injected tracer and the CT X-rays. The combined effective dose for a standard whole-body scan typically falls in the range of 10 to 25 millisieverts (mSv), with most estimates landing around 14 to 17 mSv. For context, the average person receives about 3 mSv per year from natural background radiation, so a PET/CT delivers roughly four to six years’ worth of background exposure in a single session.
This is higher than many conventional imaging tests, which is why PET/CT is ordered when the clinical question genuinely warrants it rather than as a routine screening tool. The benefit of accurately staging a cancer or detecting recurrence generally outweighs this radiation risk, but each scan should be clinically justified.
For pregnant women, the situation requires careful consideration. Ultrasound and MRI are preferred because they don’t involve ionizing radiation. However, the American College of Obstetricians and Gynecologists notes that when radiation-based imaging is medically necessary, the doses used in diagnostic tests are much lower than the threshold associated with fetal harm, and needed imaging should not be withheld from a pregnant patient.
Total-Body PET Scanners
Conventional PET/CT scanners have a relatively short detector ring, meaning they capture only a portion of the body at a time and must scan in segments. A newer generation of total-body PET scanners extends the detector array to nearly two meters, covering the entire body simultaneously. The sensitivity gains are dramatic: up to 68 times higher than conventional systems.
This leap in sensitivity opens several practical advantages. Scans can be completed faster, in some cases within a single breath-hold for certain body regions, which reduces blurring from breathing and movement. The tracer dose can be reduced by as much as 40-fold while still producing diagnostic-quality images. One study found that using one-tenth the standard tracer dose on a total-body scanner produced images and metabolic measurements equivalent to full-dose scans on conventional machines. Lower doses mean less radiation exposure, which is particularly relevant for patients who need repeated scans over the course of treatment.
These scanners are currently available at a limited number of medical centers, with commercial systems from several manufacturers offering axial fields of view ranging from about 106 cm to 194 cm. As the technology becomes more widely installed, it has the potential to make PET/CT safer and more accessible, especially for pediatric patients and others where minimizing radiation is a high priority.